# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Net loss attributable to common shareholders for the six months ended June 30, 2024, was €21.9 million, or a €0.46 basic loss p...
Guggenheim analyst Michael Schmidt initiates coverage on Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Targ...
NANOBIOTIX (NASDAQ:NBTX) today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evalu...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluati...
Based on the current operating plan and financial projections, Nanobiotix anticipates that the cash and cash equivalents of €58...
Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration ...